UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Amendment No. 3 to
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 9, 2008
Synergy Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Florida |
|
333-131722 |
|
20-3823853 |
(State or other jurisdiction |
|
(Commission |
|
IRS Employer |
of incorporation or organization) |
|
File Number) |
|
Identification No.) |
420 Lexington Avenue, Suite 1609 |
New York, NY 10170 |
(Address of principal executive offices) |
Registrants telephone number, including area code: (212) 297-0020
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
EXPLANATORY NOTE
This Amendment No. 3 to our Current Report on Form 8-K is being filed solely for the purpose of filing Exhibit 16.1. This amendment speaks as of the original filing date of our Current Report on Form 8-K and has not been updated to reflect events occurring subsequent to the original filing date.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
16.1 Letter on Change of Certifying Accountant
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 3, 2008
|
SYNERGY PHARMACEUTICALS, INC. |
|
|
|
|
|
|
|
|
By: |
/s/ Gary S. Jacob |
|
Gary S. Jacob, Ph.D. |
|
|
President and Acting Chief Executive Officer |
2